Lars Lannfelt & BioArctic
4 shared events · Importance 3 · Last updated May 28, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Business
Lars Lannfelt: Lars Lannfelt was re-elected as an ordinary board member of BioArctic.
BioArctic: BioArctic held its Annual General Meeting, making several key resolutions including dividend payment, board re-elections, and approval of an incentive program, which directly impacts its corporate governance and shareholder value.
May 28, 2026 · 9 articles
Tech
Lars Lannfelt: Lars Lannfelt is the researcher whose work at Uppsala University led to the discovery of the Arctic mutation and the development of Leqembi.
BioArctic: BioArctic is the central actor, announcing the first Swedish patient treated with Leqembi and holding Nordic commercialization rights with Eisai. The launch supports its royalty and milestone revenue stream, though the negative NT-radet reimbursement recommendation limits near-term Swedish sales.
Sep 22, 2026 · 7 articles
Business
Lars Lannfelt: Professor Lars Lannfelt's discovery of the Arctic mutation in Alzheimer's disease formed the basis for the development of Lecanemab by BioArctic.
BioArctic: BioArctic, in collaboration with Eisai, developed Lecanemab and is set to receive approximately SEK 880 million in royalties from the projected sales, indicating a positive financial outlook for the company.
May 15, 2026 · 6 articles
ERGEN INTELLIGENCE
Explore this relationship live
Track how Lars Lannfelt and BioArctic interact across events, view sentiment trends, and discover connected entities.
Open Dashboard